BRD4 inhibitor IBET upregulates p27kip/cip protein stability in neuroendocrine tumor cells. Issue 4 (3rd April 2017)

• Record Type: Journal Article
• Authors: Wang, Lei; Matkar, Smita; Xie, Gengchen; An, Chiying; He, Xin; Kong, Xiangchen; Liu, Xiuheng; Hua, Xianxin
• Is Part Of: Cancer biology & therapy. Volume 18:Issue 4(2017)
• Page Start: 229
• Page End: 236
• Publication Date: 2017-04-03
• Subjects: Brd4 -- IBET -- p27 -- neuroendocrine tumor -- Skp2; 616.99406
• DOI: 10.1080/15384047.2017.1294291
• Languages: English
• ISSNs: 1538-4047

Abstract

ABSTRACT: The prevalence of neuroendocrine tumors (NETs) has recently been increasing. Although various drugs such as Octreotide and its analogs show certain efficacy, NETs in many patients progress and metastasize. It is desirable to develop new interventions to improve the therapy. Here we show that human neuroendocrine tumor BON cells are resistant to several drugs commonly used for NET therapy, including Octreotide that activates somatostatin receptor-induced anti-proliferation, and Capecitabine and Temozolimide that damage DNA. In contrast, an inhibitor (IBET) to an epigenetic regulator, Brd4 that binds acetylated histones and upregulates transcription of multiple genes including protooncogene c-Myc, potently inhibited the NET cells. We found that IBET increased the protein levels of cyclin-dependent kinase (CDK) inhibitor p27 kip/cip (or p27), but not its mRNA levels. Moreover, the p27 induction at protein level by IBET was at least partly through increasing the protein stability of p27. The increased protein stability of p27 likely resulted from IBET-mediated suppression of Skp2, an E3 ligase that can mediate p27 degradation by increasing its ubiquitinylation. These findings unravel a new mechanism whereby the IBET-induced repression of proliferation of neuroendocrine cells.